Net risk reclassification p values: valid or misleading?

J Natl Cancer Inst. 2014 Apr;106(4):dju041. doi: 10.1093/jnci/dju041. Epub 2014 Mar 28.

Abstract

Background: The Net Reclassification Index (NRI) and its P value are used to make conclusions about improvements in prediction performance gained by adding a set of biomarkers to an existing risk prediction model. Although proposed only 5 years ago, the NRI has gained enormous traction in the risk prediction literature. Concerns have recently been raised about the statistical validity of the NRI.

Methods: Using a population dataset of 10000 individuals with an event rate of 10.2%, in which four biomarkers have no predictive ability, we repeatedly simulated studies and calculated the chance that the NRI statistic provides a positive statistically significant result. Subjects for training data (n = 420) and test data (n = 420 or 840) were randomly selected from the population, and corresponding NRI statistics and P values were calculated. For comparison, the change in the area under the receiver operating characteristic curve and likelihood ratio statistics were calculated.

Results: We found that rates of false-positive conclusions based on the NRI statistic were unacceptably high, being 63.0% in the training datasets and 18.8% to 34.4% in the test datasets. False-positive conclusions were rare when using the change in the area under the curve and occurred at the expected rate of approximately 5.0% with the likelihood ratio statistic.

Conclusions: Conclusions about biomarker performance that are based primarily on a statistically significant NRI statistic should be treated with skepticism. Use of NRI P values in scientific reporting should be halted.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Area Under Curve
  • Biomarkers, Tumor*
  • Databases, Factual
  • False Positive Reactions
  • Humans
  • Models, Statistical*
  • Odds Ratio
  • Predictive Value of Tests*
  • Prognosis
  • ROC Curve
  • Risk Assessment*
  • Risk Factors

Substances

  • Biomarkers, Tumor